
In the post-COVID-19 era, Adonat® Premium SAMe (S-adenosyl-methionine) can answer the changed health priorities of global consumers, looking for effective natural-based ingredients to sustain the body’s well-being, brain health, and cognitive functions.
Why a new white paper on Adonat® Premium SAMe
Science and innovation do not stand still, especially when it comes to lifespan and human health. Knowing the new market scenarios, new consumer needs and their problems and concerns is now crucial to being a key player in the field of human health and nutrition.
With this new White Paper, Gnosis by Lesaffre presents a deep dive into Adonat® Premium SAMe insights, analyzing major market trends and offering a wide overview of mechanisms actions, clinical data, and applications either on the consolidated field – Mood, Cognitive, Liver, Joint, and longevity – and more new ones, especially in the emerging Brain health sector – epigenetics, stress&anxiety, attention, concentration, motor-cortex function.
Downloading the White Paper you will discover:
- What is SAMe and its essential metabolic functions
- How SAMe works in Human Health
- Gnosis expertise and quality in Adonat® Premium SAMe
Gnosis: The first in SAMe
With over 30 years of manufacturing, both for the nutraceutical and pharmaceutical market, Gnosis is today the key leader in SAMe, and by the end of this year, it will double the capacity of its GMP manufacturing operations in Sant’Antonino (CH), to better differentiate Adonat® Premium SAMe proposal.
Get the occasion to know the major milestones achieved by the company on the development of this fermented-derived ingredient (proprietary patented process of Saccharomyces cerevisiae culture) and the best quality offered, download now the White Paper.
Latest news & videos

- Corporate
- Digestion & Gut
- News
- Jun 06, 2025
Biotic Live: A Successful First Edition Exploring the Power of Probiotic Yeasts
Gnosis by Lesaffre recently hosted the first edition of Biotic Live, a unique event...

- Mobility & Joint
- MyCondro®
- News
- Jun 05, 2025
Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day
At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by...

- MenaQ7®
- Mobility & Joint
- News
- Jun 02, 2025
Supplementation with Menaquinone-7 (as MenaQ7®) Slows the Progression of Coronary Artery Calcification
The first results from the VitaK-CAC Trial, “Menaquinone-7 Slows Down Progression of Coronary Artery...